［1］ Fujisawa C，Castellot JJ Jr. Matrix production and remodeling as therapeutic targets for uterine leiomyoma［J］. J Cell Commun Signal，2014，8（3）：179-194.
［2］ Turan V，Bedoschi G，Moy F，et al. Safety and feasibility of performing two consecutive ovarian stimulation cycles with the use of letrozole-gonadotropin protocol for fertility preservation in breast cancer patients［J］. Fertil Steril，2013，100（6）:1681-1685.
［3］ Duhan N，Madaan S，Sen J. Role of the aromatase inhibitor letrozole in the management of uterine leiomyomas in premenopausal women［J］. Eur J Obstet Gynecol Reprod Biol，2013，171（2）：329-332.
［4］ Gurates B，Parmaksiz C，Kilic G，et al. Treatment of symptomatic uterine leiomyoma with letrozole［J］. Reprod Biomed Online，2008，17（4）:569-574.
［5］ Gurates B,Pramaksiz C,Kilic G,et al.Treatment of symptomatic uterine leiomyoma with letrozole［J］.Reprod Biomed Online,2008,17(4):569-574.
［6］ Mitwally M，Casper R．The ammatase inhibitor，letroole：a promising altemative for clomiphene citrate for induction of ovulation［J］．Fertil Steril，2000，74(3)：535．
［7］ Shozu M，Murakami K，Segawa T，et al. Successful treatment of a symptomatic uterine leiomyoma in a perimenopausal woman with a nonsteroidal aromatase inhibitor［J］. Fertil Steril，2003，79（3）: 628-631.
［8］ Kar S. Current evidence supporting "letrozole" for ovulation induction［J］. J Hum Reprod Sci，2013，6（2）:93-98.
